DANONE (BSN.DE) Fundamental Analysis & Valuation

FRA:BSNFR0000120644

Current stock price

68.2 EUR
-0.3 (-0.44%)
Last:

This BSN.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. BSN.DE Profitability Analysis

1.1 Basic Checks

  • BSN had positive earnings in the past year.
  • In the past year BSN had a positive cash flow from operations.
  • BSN had positive earnings in each of the past 5 years.
  • Each year in the past 5 years BSN had a positive operating cash flow.
BSN.DE Yearly Net Income VS EBIT VS OCF VS FCFBSN.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

1.2 Ratios

  • BSN has a better Return On Assets (4.03%) than 60.32% of its industry peers.
  • BSN's Return On Equity of 10.73% is fine compared to the rest of the industry. BSN outperforms 61.90% of its industry peers.
  • BSN has a better Return On Invested Capital (7.75%) than 68.25% of its industry peers.
  • BSN had an Average Return On Invested Capital over the past 3 years of 7.51%. This is in line with the industry average of 7.03%.
  • The 3 year average ROIC (7.51%) for BSN is below the current ROIC(7.75%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 4.03%
ROE 10.73%
ROIC 7.75%
ROA(3y)3.48%
ROA(5y)3.34%
ROE(3y)9.16%
ROE(5y)8.75%
ROIC(3y)7.51%
ROIC(5y)7.21%
BSN.DE Yearly ROA, ROE, ROICBSN.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5 10 15

1.3 Margins

  • BSN has a Profit Margin of 6.66%. This is in the better half of the industry: BSN outperforms 66.67% of its industry peers.
  • BSN's Profit Margin has declined in the last couple of years.
  • The Operating Margin of BSN (13.43%) is better than 85.71% of its industry peers.
  • BSN's Operating Margin has been stable in the last couple of years.
  • With an excellent Gross Margin value of 50.62%, BSN belongs to the best of the industry, outperforming 87.30% of the companies in the same industry.
  • BSN's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 13.43%
PM (TTM) 6.66%
GM 50.62%
OM growth 3Y3.21%
OM growth 5Y-0.93%
PM growth 3Y24.9%
PM growth 5Y-4.13%
GM growth 3Y3.2%
GM growth 5Y1.04%
BSN.DE Yearly Profit, Operating, Gross MarginsBSN.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30 40 50

4

2. BSN.DE Health Analysis

2.1 Basic Checks

  • BSN has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • The number of shares outstanding for BSN has been reduced compared to 1 year ago.
  • The number of shares outstanding for BSN has been reduced compared to 5 years ago.
  • Compared to 1 year ago, BSN has a worse debt to assets ratio.
BSN.DE Yearly Shares OutstandingBSN.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M
BSN.DE Yearly Total Debt VS Total AssetsBSN.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B 40B

2.2 Solvency

  • BSN has an Altman-Z score of 2.37. This is not the best score and indicates that BSN is in the grey zone with still only limited risk for bankruptcy at the moment.
  • BSN has a Altman-Z score of 2.37. This is in the better half of the industry: BSN outperforms 60.32% of its industry peers.
  • The Debt to FCF ratio of BSN is 5.29, which is a neutral value as it means it would take BSN, 5.29 years of fcf income to pay off all of its debts.
  • The Debt to FCF ratio of BSN (5.29) is better than 69.84% of its industry peers.
  • A Debt/Equity ratio of 0.73 indicates that BSN is somewhat dependend on debt financing.
  • BSN has a Debt to Equity ratio of 0.73. This is in the lower half of the industry: BSN underperforms 61.90% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.73
Debt/FCF 5.29
Altman-Z 2.37
ROIC/WACC1.22
WACC6.35%
BSN.DE Yearly LT Debt VS Equity VS FCFBSN.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B

2.3 Liquidity

  • A Current Ratio of 0.90 indicates that BSN may have some problems paying its short term obligations.
  • The Current ratio of BSN (0.90) is worse than 76.19% of its industry peers.
  • A Quick Ratio of 0.75 indicates that BSN may have some problems paying its short term obligations.
  • BSN's Quick ratio of 0.75 is in line compared to the rest of the industry. BSN outperforms 42.86% of its industry peers.
Industry RankSector Rank
Current Ratio 0.9
Quick Ratio 0.75
BSN.DE Yearly Current Assets VS Current LiabilitesBSN.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B

4

3. BSN.DE Growth Analysis

3.1 Past

  • BSN shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 4.68%.
  • BSN shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 2.61% yearly.
  • The Revenue has decreased by -0.34% in the past year.
  • BSN shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 2.93% yearly.
EPS 1Y (TTM)4.68%
EPS 3Y3.47%
EPS 5Y2.61%
EPS Q2Q%3.28%
Revenue 1Y (TTM)-0.34%
Revenue growth 3Y-0.46%
Revenue growth 5Y2.93%
Sales Q2Q%-0.54%

3.2 Future

  • Based on estimates for the next years, BSN will show a small growth in Earnings Per Share. The EPS will grow by 7.81% on average per year.
  • The Revenue is expected to grow by 4.25% on average over the next years.
EPS Next Y7.51%
EPS Next 2Y7.63%
EPS Next 3Y7.85%
EPS Next 5Y7.81%
Revenue Next Year2.65%
Revenue Next 2Y3.28%
Revenue Next 3Y3.54%
Revenue Next 5Y4.25%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
BSN.DE Yearly Revenue VS EstimatesBSN.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 10B 20B 30B
BSN.DE Yearly EPS VS EstimatesBSN.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 1 2 3 4 5

4

4. BSN.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • BSN is valuated rather expensively with a Price/Earnings ratio of 17.95.
  • BSN's Price/Earnings is on the same level as the industry average.
  • The average S&P500 Price/Earnings ratio is at 25.54. BSN is valued slightly cheaper when compared to this.
  • BSN is valuated correctly with a Price/Forward Earnings ratio of 16.69.
  • BSN's Price/Forward Earnings is on the same level as the industry average.
  • BSN's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 22.70.
Industry RankSector Rank
PE 17.95
Fwd PE 16.69
BSN.DE Price Earnings VS Forward Price EarningsBSN.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of BSN is on the same level as its industry peers.
  • Based on the Price/Free Cash Flow ratio, BSN is valued a bit cheaper than the industry average as 65.08% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 17.05
EV/EBITDA 9.39
BSN.DE Per share dataBSN.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30 40

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates BSN does not grow enough to justify the current Price/Earnings ratio.
  • BSN has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)2.39
PEG (5Y)6.87
EPS Next 2Y7.63%
EPS Next 3Y7.85%

6

5. BSN.DE Dividend Analysis

5.1 Amount

  • BSN has a Yearly Dividend Yield of 3.24%. Purely for dividend investing, there may be better candidates out there.
  • Compared to an average industry Dividend Yield of 2.31, BSN pays a bit more dividend than its industry peers.
  • Compared to an average S&P500 Dividend Yield of 1.89, BSN pays a better dividend.
Industry RankSector Rank
Dividend Yield 3.24%

5.2 History

  • The dividend of BSN has a limited annual growth rate of 0.46%.
Dividend Growth(5Y)0.46%
Div Incr Years3
Div Non Decr Years4
BSN.DE Yearly Dividends per shareBSN.DE Yearly Dividends per shareYearly Dividends per share 2019 2020 2021 2022 2023 2024 2025 2026 1 2 3 4

5.3 Sustainability

  • BSN pays out 75.94% of its income as dividend. This is not a sustainable payout ratio.
  • The dividend of BSN is growing, but earnings are growing more, so the dividend growth is sustainable.
DP75.94%
EPS Next 2Y7.63%
EPS Next 3Y7.85%
BSN.DE Yearly Income VS Free CF VS DividendBSN.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B 2.5B
BSN.DE Dividend Payout.BSN.DE Dividend Payout, showing the Payout Ratio.BSN.DE Dividend Payout.PayoutRetained Earnings

BSN.DE Fundamentals: All Metrics, Ratios and Statistics

DANONE

FRA:BSN (3/23/2026, 7:00:00 PM)

68.2

-0.3 (-0.44%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupFood, Beverage & Tobacco
GICS IndustryFood Products
Earnings (Last)02-20
Earnings (Next)04-22
Inst Owners53.9%
Inst Owner ChangeN/A
Ins Owners0%
Ins Owner ChangeN/A
Market Cap46.47B
Revenue(TTM)27.28B
Net Income(TTM)1.82B
Analysts75.15
Price Target80.77 (18.43%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 3.24%
Yearly Dividend2.15
Dividend Growth(5Y)0.46%
DP75.94%
Div Incr Years3
Div Non Decr Years4
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.13%
PT rev (3m)-0.1%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-2.02%
EPS NY rev (3m)-2.43%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.77%
Revenue NY rev (3m)-0.77%
Valuation
Industry RankSector Rank
PE 17.95
Fwd PE 16.69
P/S 1.7
P/FCF 17.05
P/OCF 12.29
P/B 2.75
P/tB N/A
EV/EBITDA 9.39
EPS(TTM)3.8
EY5.57%
EPS(NY)4.09
Fwd EY5.99%
FCF(TTM)4
FCFY5.86%
OCF(TTM)5.55
OCFY8.13%
SpS40.04
BVpS24.83
TBVpS-9.13
PEG (NY)2.39
PEG (5Y)6.87
Graham Number46.07
Profitability
Industry RankSector Rank
ROA 4.03%
ROE 10.73%
ROCE 12.04%
ROIC 7.75%
ROICexc 9.68%
ROICexgc 76.66%
OM 13.43%
PM (TTM) 6.66%
GM 50.62%
FCFM 9.99%
ROA(3y)3.48%
ROA(5y)3.34%
ROE(3y)9.16%
ROE(5y)8.75%
ROIC(3y)7.51%
ROIC(5y)7.21%
ROICexc(3y)9.24%
ROICexc(5y)8.74%
ROICexgc(3y)70.2%
ROICexgc(5y)59.95%
ROCE(3y)11.59%
ROCE(5y)10.94%
ROICexgc growth 3Y20.15%
ROICexgc growth 5Y16.9%
ROICexc growth 3Y6.6%
ROICexc growth 5Y4.3%
OM growth 3Y3.21%
OM growth 5Y-0.93%
PM growth 3Y24.9%
PM growth 5Y-4.13%
GM growth 3Y3.2%
GM growth 5Y1.04%
F-Score7
Asset Turnover0.61
Health
Industry RankSector Rank
Debt/Equity 0.73
Debt/FCF 5.29
Debt/EBITDA 2.46
Cap/Depr 77.86%
Cap/Sales 3.87%
Interest Coverage 21.06
Cash Conversion 75.3%
Profit Quality 150.06%
Current Ratio 0.9
Quick Ratio 0.75
Altman-Z 2.37
F-Score7
WACC6.35%
ROIC/WACC1.22
Cap/Depr(3y)69.82%
Cap/Depr(5y)67.75%
Cap/Sales(3y)3.44%
Cap/Sales(5y)3.55%
Profit Quality(3y)197.16%
Profit Quality(5y)188.14%
High Growth Momentum
Growth
EPS 1Y (TTM)4.68%
EPS 3Y3.47%
EPS 5Y2.61%
EPS Q2Q%3.28%
EPS Next Y7.51%
EPS Next 2Y7.63%
EPS Next 3Y7.85%
EPS Next 5Y7.81%
Revenue 1Y (TTM)-0.34%
Revenue growth 3Y-0.46%
Revenue growth 5Y2.93%
Sales Q2Q%-0.54%
Revenue Next Year2.65%
Revenue Next 2Y3.28%
Revenue Next 3Y3.54%
Revenue Next 5Y4.25%
EBIT growth 1Y3.01%
EBIT growth 3Y2.73%
EBIT growth 5Y1.96%
EBIT Next Year36.75%
EBIT Next 3Y14.85%
EBIT Next 5Y11.54%
FCF growth 1Y-6.26%
FCF growth 3Y9.25%
FCF growth 5Y6.33%
OCF growth 1Y-1.31%
OCF growth 3Y8.46%
OCF growth 5Y4.96%

DANONE / BSN.DE Fundamental Analysis FAQ

What is the fundamental rating for BSN stock?

ChartMill assigns a fundamental rating of 5 / 10 to BSN.DE.


What is the valuation status for BSN stock?

ChartMill assigns a valuation rating of 4 / 10 to DANONE (BSN.DE). This can be considered as Fairly Valued.


How profitable is DANONE (BSN.DE) stock?

DANONE (BSN.DE) has a profitability rating of 7 / 10.


What is the earnings growth outlook for DANONE?

The Earnings per Share (EPS) of DANONE (BSN.DE) is expected to grow by 7.51% in the next year.


Is the dividend of DANONE sustainable?

The dividend rating of DANONE (BSN.DE) is 6 / 10 and the dividend payout ratio is 75.94%.